Copa Holdings (CPA)
(Delayed Data from NYSE)
$97.89 USD
+0.09 (0.09%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $97.94 +0.05 (0.05%) 4:42 PM ET
2-Buy of 5 2
A Value D Growth D Momentum B VGM
Price, Consensus and EPS Surprise
CPA 97.89 +0.09(0.09%)
Will CPA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CPA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CPA
Implied Volatility Surging for Copa Holdings (CPA) Stock Options
Wall Street Analysts Predict a 51.98% Upside in Copa Holdings (CPA): Here's What You Should Know
CPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Copa Holdings (CPA) Stock?
Joby Aviation, Inc. (JOBY) Reports Q3 Loss, Misses Revenue Estimates
What's in the Offing for Seanergy Maritime in Q3 Earnings?
Other News for CPA
CPA Makes Notable Cross Below Critical Moving Average
Colgate-Palmolive: Hold Rating Amid Strong Performance and Limited Upside Potential
Bank of America Securities Keeps Their Buy Rating on Colgate-Palmolive (CL)
Coinbase initiated, Edwards Lifesciences upgraded: Wall Street’s top analyst cal
Evercore ISI Reaffirms Their Buy Rating on Colgate-Palmolive (CL)